BEVALTI
DEAD

Serial Number

98771026

Owner

SAREPTA THERAPEUTICS, INC.

Attorney

Maury M. Tepper, III

Filing Date

Sep 26, 2024

Add to watchlist:

No watchlists yet
View on USPTO

BEVALTI Trademark

Serial Number: 98771026

BEVALTI is a trademark filed by SAREPTA THERAPEUTICS, INC. on September 26, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

SAREPTA THERAPEUTICS, INC. (109 trademarks)

215 FIRST STREET, SUITE 7
CAMBRIDGE, MA 02142

Entity Type: 03

Trademark Details

Filing Date

September 26, 2024

Registration Date

Not Registered

Goods & Services

Medical services; providing health information

Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases

Medical training and teaching

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Oct 20, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 20, 2025 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 4, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 4, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 4, 2025 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 23, 2025 GNRN
NON-FINAL ACTION E-MAILED
Apr 23, 2025 GNRT
NON-FINAL ACTION WRITTEN
Apr 23, 2025 CNRT
ASSIGNED TO EXAMINER
Apr 15, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 14, 2025 NWOS
NEW APPLICATION ENTERED
Sep 26, 2024 NWAP